Avorn J, Bohn R L, Mogun H, Gurwitz J H, Monane M, Everitt D, Walker A
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Am J Med. 1995 Jul;99(1):48-54. doi: 10.1016/s0002-9343(99)80104-1.
Despite the widespread use of neuroleptic medications for the elderly, little is known about the frequency of treatment for drug-induced parkinsonian syndromes in this age group, particularly with L-dopa-type drugs, which are more appropriate for the treatment of true idiopathic Parkinson's disease.
We identified 3,512 patients aged 65 to 99 enrolled in a large state Medicaid program who were newly prescribed a drug to treat parkinsonian symptoms. Controls were comparable program enrollees of similar age who had not been prescribed an antiparkinsonian drug. In a case-control study, we evaluated the use of neuroleptic drugs in the 90 days before initiation of antiparkinsonian therapy.
Patients taking neuroleptics were 5.4 times more likely to begin antiparkinsonian medication than were nonusers (95% confidence interval [CI] 4.8 to 6.1). They also had a greater than two-fold increase in risk of beginning therapy with a dopaminergic drug specific for idiopathic Parkinson's disease, not generally indicated for treatment of drug-induced parkinsonism (adjusted odds ratio 2.2, 95% CI 1.9 to 2.7). Clear dose-response relationships were demonstrated, as were differences among neuroleptics. Among all patients started on dopaminergic drugs in this population, 37% of such therapy was attributable to prior neuroleptic use. Continuation of the neuroleptic persisted in 71% of patients so treated.
Neuroleptic use is a common cause of extrapyramidal dysfunction in the elderly, and the side effect is frequently treated by adding an anticholinergic or dopaminergic drug to the regimen. The use of anticholinergic drugs presents risks of additional drug side effects; the use of dopaminergic drugs, generally not appropriate for drug-induced parkinsonian syndrome, suggests that extrapyramidal neuroleptic side effects may often be mistaken for idiopathic Parkinson's disease in older patients.
尽管抗精神病药物在老年人中广泛使用,但对于该年龄组药物性帕金森综合征的治疗频率知之甚少,尤其是左旋多巴类药物,这类药物更适合治疗真正的特发性帕金森病。
我们在一个大型州医疗补助项目中确定了3512名年龄在65至99岁之间且新开具治疗帕金森症状药物的患者。对照组是年龄相仿但未开具抗帕金森药物的该项目参保者。在一项病例对照研究中,我们评估了在开始抗帕金森治疗前90天内抗精神病药物的使用情况。
服用抗精神病药物的患者开始使用抗帕金森药物的可能性是非使用者的5.4倍(95%置信区间[CI] 4.8至6.1)。他们开始使用针对特发性帕金森病的多巴胺能药物进行治疗的风险也增加了两倍多,而这类药物通常不用于治疗药物性帕金森综合征(调整后的优势比为2.2,95% CI 1.9至2.7)。研究显示了明确的剂量反应关系以及不同抗精神病药物之间的差异。在该人群中开始使用多巴胺能药物的所有患者中,37%的此类治疗归因于先前使用抗精神病药物。在接受此类治疗的患者中,71%继续使用抗精神病药物。
使用抗精神病药物是老年人锥体外系功能障碍的常见原因,这种副作用通常通过在治疗方案中添加抗胆碱能或多巴胺能药物来治疗。使用抗胆碱能药物存在额外药物副作用的风险;使用多巴胺能药物(通常不适合药物性帕金森综合征)表明,在老年患者中,锥体外系抗精神病药物副作用可能常常被误诊为特发性帕金森病。